▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] The Financial Supervisory Service on Aug. 17 announced strengthened disclosure requirements for biotechnology and pharmaceutical companies starting with their third-quarter earnings r...
[THE INVESTOR] A growing number of Korea’s biotech and pharmaceutical companies are pushing the boundaries of conventional product portfolios that depend heavily on imported therapies and generic dr...
[THE INEVSTOR] Kyongbo Pharmaceutical, an affiliate of Chong Kun Dang Holdings, said on Aug. 14 that it was awarded the Good Manufacturing Practice certificate from the French health regulator for i...
[THE INVESTOR] Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, said on Aug. 14 that it will begin clinical trials of its drug candidate to treat acute pancreatitis, marking ...
[THE INVESTOR] In Korea, laser eye surgery, performed as LASIK or LASEK, has become a common medical procedure over the past decade. But for many patients, improved eyesight comes at the cost of a n...
[THE INVESTOR] The Korean government has announced that it will designate the biotechnology industry as one of the country’s innovation sectors to fuel the economy by removing unnecessary regulation...
[THE INVESTOR] Samsung Group Vice Chairman Lee Jae-yong told top government officials on Aug. 6 that he is willing to get the biopharmaceutical business back on track amid the prosecution’s ongoing ...
[THE INVESTOR] Celltrion said on Aug. 7 that it has submitted an application to UK health regulators to initiate phase 1 clinical trials of CT-P17, its copy version of the world’s top selling drug ...
[THE INVESTOR] Bukwang Pharmaceutical said on Aug. 7 that it has completed patient enrollment for phase 2b clinical trials of its type 2 diabetes drug candidate MLR-1023. The drug maker said it ex...
[THE INVESTOR] Shares of Korean biotech firm Nature Cell surged over 14 percent on Aug. 6, the first trading day after CEO Ra Jeong-chan was indicted on charges of manipulating the stock price wit...
[THE INVESTOR] Korea’s drug safety watchdog said Monday that it has banned Daebong LS, a local maker of valsartan, from selling and making the active ingredient meant to treat high blood pressure ov...
[THE INVESTOR] Daewoong Pharmaceutical 's self-developed botulinum toxin Nabota is highly expected to receive marketing authorization from the US Food and Drug Administration by February next year ...
[THE INVESTOR] Alteogen said on Aug. 2 that it has received orphan drug designation for ALT-P7, a gastric cancer drug candidate with antibody-drug conjugate, from the US Food and Drug Administratio...
[THE INVESTOR] Korean biopharmaceutical firm Celltrion said on Aug. 2 that its breast cancer biosimilar has been approved by Australia’s regulatory body. The Therapeutic Goods Administration app...
[THE INVESTOR] Prosecutors opened an investigation on Aug. 1 into a financial regulator’s complaint that a pharmaceutical affiliate of Samsung Electronics breached disclosure rules regarding a call ...
SM, JYP, YG shares jump on Q2 earnings
FSS announces tougher disclosure rules for biotech stocks
Gov’t decides not to cancel Jin Air license
LG to launch world’s largest micro LED TV at IFA
Korean biotechs’ drug candidates in phase 3 clinical trials
SoftBank Ventures leads W10b investment in Bepro11
Bitcoin ATM Coinme to make Korea debut in Q4
Shinhan Financial resumes talks to acquire ING Life for W2.4tr
August 19, 2018
